229 related articles for article (PubMed ID: 2065848)
1. Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients.
Sanke T; Hanabusa T; Nakano Y; Oki C; Okai K; Nishimura S; Kondo M; Nanjo K
Diabetologia; 1991 Feb; 34(2):129-32. PubMed ID: 2065848
[TBL] [Abstract][Full Text] [Related]
2. Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus.
Hanabusa T; Kubo K; Oki C; Nakano Y; Okai K; Sanke T; Nanjo K
Diabetes Res Clin Pract; 1992 Jan; 15(1):89-96. PubMed ID: 1541240
[TBL] [Abstract][Full Text] [Related]
3. Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus.
Eriksson J; Nakazato M; Miyazato M; Shiomi K; Matsukura S; Groop L
Diabetologia; 1992 Mar; 35(3):291-3. PubMed ID: 1563587
[TBL] [Abstract][Full Text] [Related]
4. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus.
Enoki S; Mitsukawa T; Takemura J; Nakazato M; Aburaya J; Toshimori H; Matsukara S
Diabetes Res Clin Pract; 1992 Jan; 15(1):97-102. PubMed ID: 1541241
[TBL] [Abstract][Full Text] [Related]
5. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes.
Ludvik B; Lell B; Hartter E; Schnack C; Prager R
Diabetes; 1991 Dec; 40(12):1615-9. PubMed ID: 1756902
[TBL] [Abstract][Full Text] [Related]
6. Deficiency of total and nonglycosylated amylin in plasma characterizes subjects with impaired glucose tolerance and type 2 diabetes.
Mäkimattila S; Fineman MS; Yki-Järvinen H
J Clin Endocrinol Metab; 2000 Aug; 85(8):2822-7. PubMed ID: 10946889
[TBL] [Abstract][Full Text] [Related]
7. Parallel changes of proinsulin and islet amyloid polypeptide in glucose intolerance.
MacNamara CM; Barrow BA; Manley SE; Levy JC; Clark A; Turner RC
Diabetes Res Clin Pract; 2000 Oct; 50(2):117-26. PubMed ID: 10960722
[TBL] [Abstract][Full Text] [Related]
8. Increased plasma amylin in type 1 diabetic patients after kidney and pancreas transplantation: A sign of impaired beta-cell function?
Stadler M; Anderwald C; Karer T; Tura A; Kästenbauer T; Auinger M; Bieglmayer C; Wagner O; Kronenberg F; Nowotny P; Pacini G; Prager R
Diabetes Care; 2006 May; 29(5):1031-8. PubMed ID: 16644633
[TBL] [Abstract][Full Text] [Related]
9. Hyperamylinemia is associated with hyperinsulinemia in the glucose-tolerant, insulin-resistant offspring of two Mexican-American non-insulin-dependent diabetic parents.
Gulli G; Rossetti L; DeFronzo RA
Metabolism; 1997 Oct; 46(10):1157-61. PubMed ID: 9322799
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of insulin secretion, but normal peripheral insulin sensitivity, in a patient with a malignant endocrine pancreatic tumour producing high amounts of an islet amyloid polypeptide-like molecule.
Stridsberg M; Berne C; Sandler S; Wilander E; Oberg K
Diabetologia; 1993 Sep; 36(9):843-9. PubMed ID: 8405756
[TBL] [Abstract][Full Text] [Related]
11. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans.
Hartter E; Svoboda T; Ludvik B; Schuller M; Lell B; Kuenburg E; Brunnbauer M; Woloszczuk W; Prager R
Diabetologia; 1991 Jan; 34(1):52-4. PubMed ID: 2055340
[TBL] [Abstract][Full Text] [Related]
12. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Jones IR; Owens DR; Luzio S; Williams S; Hayes TM
Diabetologia; 1989 Sep; 32(9):668-77. PubMed ID: 2676668
[TBL] [Abstract][Full Text] [Related]
13. Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2).
Zapecka-Dubno B; Czyzyk A; Dworak A; Bak MI
Arzneimittelforschung; 1999 Apr; 49(4):330-4. PubMed ID: 10337452
[TBL] [Abstract][Full Text] [Related]
14. Role of islet amyloid polypeptide secretion in insulin-resistant humans.
Kautzky-Willer A; Thomaseth K; Pacini G; Clodi M; Ludvik B; Streli C; Waldhäusl W; Prager R
Diabetologia; 1994 Feb; 37(2):188-94. PubMed ID: 8163054
[TBL] [Abstract][Full Text] [Related]
15. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
Rachman J; Payne MJ; Levy JC; Barrow BA; Holman RR; Turner RC
Diabetes Care; 1998 May; 21(5):810-6. PubMed ID: 9589246
[TBL] [Abstract][Full Text] [Related]
16. Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity.
Mather KJ; Paradisi G; Leaming R; Hook G; Steinberg HO; Fineberg N; Hanley R; Baron AD
Diabetes Metab Res Rev; 2002; 18(2):118-26. PubMed ID: 11994903
[TBL] [Abstract][Full Text] [Related]
17. Effects of ciglitazone on endogenous plasma islet amyloid polypeptide and insulin sensitivity in obese-diabetic viable yellow mice.
Gill AM; Yen TT
Life Sci; 1991; 48(7):703-10. PubMed ID: 1990240
[TBL] [Abstract][Full Text] [Related]
18. Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans.
Kahn SE; Verchere CB; Andrikopoulos S; Asberry PJ; Leonetti DL; Wahl PW; Boyko EJ; Schwartz RS; Newell-Morris L; Fujimoto WY
Diabetes; 1998 Apr; 47(4):640-5. PubMed ID: 9568698
[TBL] [Abstract][Full Text] [Related]
19. Islet amyloid polypeptide (amylin) does not seem to be directly involved in the development of gestational diabetes mellitus.
Grigorakis SI; Alevizaki M; Rapti E; Anastasiou E; Alevizaki CC; Souvatzoglou A
Gynecol Obstet Invest; 1997; 44(1):6-10. PubMed ID: 9251946
[TBL] [Abstract][Full Text] [Related]
20. Plasma concentrations of islet amyloid polypeptide after glucagon administration in type 2 diabetic patients and non-diabetic subjects.
van Jaarsveld BC; Hackeng WH; Lips CJ; Erkelens DW
Diabet Med; 1993 May; 10(4):327-30. PubMed ID: 8508614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
